Brief: Deciphera Pharmaceuticals Announces Restructuring To Prioritize Clinical Development Programs And Streamline Commercial Operations

Deciphera Pharmaceuticals

30/11/2021 13:49

Nov 30 (Reuters) - Deciphera Pharmaceuticals Inc  DCPH.O :
    * DECIPHERA PHARMACEUTICALS ANNOUNCES RESTRUCTURING TO
PRIORITIZE
CLINICAL DEVELOPMENT PROGRAMS AND STREAMLINE COMMERCIAL
OPERATIONS
    * DECIPHERA PHARMACEUTICALS INC - WORKFORCE REDUCTION OF
APPROXIMATELY 35%
    * DECIPHERA PHARMACEUTICALS INC - CASH RUNWAY EXTENDED INTO
2024
    * DECIPHERA PHARMACEUTICALS INC - US COMMERCIAL OPERATIONS
STREAMLINED AND LAUNCHES PLANNED IN SELECT EUROPEAN MARKETS FOR
QINLOCK
    * DECIPHERA PHARMACEUTICALS INC - RESOURCES FOCUSED ON
CLINICAL
DEVELOPMENT OF VIMSELTINIB AND DCC-3116; REBASTINIB PROGRAM
DISCONTINUED
    * DECIPHERA PHARMACEUTICALS - WILL REMAIN FOCUSED ON
COMMERCIALIZATION OF QINLOCK FOR TREATMENT OF FOURTH-LINE GIST
IN U.S. WITH REDUCED COMMERCIAL TEAM
    * DECIPHERA PHARMACEUTICALS - IN EUROPE, WILL MAINTAIN
LIMITED
DIRECT COMMERCIAL PRESENCE THAT WILL SUPPORT LAUNCH OF QINLOCK
IN GERMANY AND FRANCE
    * DECIPHERA PHARMACEUTICALS INC - FURTHER CLINICAL
DEVELOPMENT OF
QINLOCK WILL BE DISCONTINUED, INCLUDING PHASE 1B/2 MEK
COMBINATION STUDY
    * DECIPHERA PHARMACEUTICALS - EXPECTS TO INITIATE PHASE 3
MOTION
STUDY FOR VIMSELTINIB FOR TREATMENT OF TENOSYNOVIAL GIANT CELL
TUMOR BEFORE END OF YEAR
    * DECIPHERA PHARMACEUTICALS INC - DECIPHERA WILL CONTINUE TO
ADVANCE CLINICAL DEVELOPMENT OF DCC-3116
    * DECIPHERA PHARMACEUTICALS - INTENDS TO CONTINUE TO INVEST
IN
DEVELOPMENT OF NEW PRODUCT CANDIDATES USING ITS NOVEL
SWITCH-CONTROL INHIBITOR APPROACH
    * DECIPHERA - EXPLORING PRECLINICAL COMBINATIONS OF DCC-3116
WITH
MULTIPLE ADDITIONAL TARGETED ONCOLOGY AGENTS WITH DIVERSE
MECHANISMS OF ACTION
    * DECIPHERA PHARMACEUTICALS INC - EXPECTS TO RECOGNIZE A
ONE-TIME
CASH CHARGE IN Q4 OF APPROXIMATELY $32 MILLION

Source text for Eikon:  ID:nBw7cqLhQa 
Further company coverage:  DCPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))